IL-8 produce by monocyte/ macrophage, endothelial cell, fibroblast, hepatocyte and PMN, is novel cytokine that activate neutrophil in H. pylori infected patient, and as a potential mediator for inflammation. This study aim to know the correlation of IL8 gastric mucosa with density of H. pylori infection in gastritis patient. Methods: We perform a cross-sectional study on H. pylori positive

gastritis patient. Degree of gastric mucosa inflammation Selleckchem MAPK inhibitor examined from gastric mucosa biopsy in anthrum and corpus with Hematoxillin-Eosin & Giemsa stain by pathologist, and evaluated base on The Updated Sydney System grade. IL8 level of gastric mucosa was examined base on ELISA method. Results: We included 65 patients, 31 male and 34 female. The age of patients 20–86 years old. Endoscopic feature of the patient were normal, superficial gastritis, erosive gastritis, ulcer in 1, 34, 23, 7 patients, respectively. IL8 gastric mucosa correlated with severity of gastric mucosa inflammation (r = 0,447; p < 0,001). And IL8 have significant correlation with density of H. pylori infection CP-673451 manufacturer (r = 0,32; p < 0,001). Conclusion: IL8 gastric mucosa significantly correlated with density of H. pylori infection in gastric mucosa. Key Word(s): 1. h pylori; 2. density;

3. IL8; Presenting Author: TINGTING WANG Additional Authors: XUEZHI ZHANG, HONG CHENG, JIANG LI, YUEMIAO ZHANG, HUI YE Corresponding Author: XUEZHI ZHANG Affiliations: Department of Integrated Traditional Chinese and Western Medicine, Peking University First Hospital; Department of Gastroenterology, Peking University First Hospital Objective: Jinghuaweikang capsules is a traditional Chinese medicine used for the treatment of Chronic Atrophic Gastritis (CAG), which has the main component of Dysphania ambrosioides and Adina pilulifera.

This study is to observe the efficacy of Jinghuaweikang capsules plus triple regimen in the treatment of CAG patients with H. pylori infection. Methods: This was a randomized controlled study. 51 patients who were endoscopically confirmed CAG with H. pylori positive [13C or 14C-urea breath test (UBT) or rapid urease test positive] were selleck enrolled, 24 males, aged 56 ± 9.87. All the patients have no H. pylori eradication backgrounds. They were randomly divided into 2 groups, Group LACJ (n = 25) were given lansoprazole (30 mg b. i. d.), amoxicillin (1000 mg b. i. d.), clarithromycin (500 mg b. i. d.), jinghuaweikang capsules (240 mg b. i. d.) for 10 days plus another 14 days only with jinghuaweikang capsules; Group LACB (n = 26) received standard quadruple regimen treatment: lansoprazole (30 mg b. i. d.), amoxicillin (1000 mg b. i. d.), clarithromycin (500 mg b. i. d.), bismuth potassium citrate (220 mg b. i. d.) for 10 days. The status of H. pylori were detected by 13C-UBT at least 4 weeks after therapy.